Matches in SemOpenAlex for { <https://semopenalex.org/work/W17295600> ?p ?o ?g. }
- W17295600 endingPage "BCBCR.S2492" @default.
- W17295600 startingPage "BCBCR.S2492" @default.
- W17295600 abstract "Biomarkers of breast cancer are necessary for prognosis and prediction to chemotherapy. Prognostic biomarkers provide information regarding outcome irrespective of therapy, while predictive biomarkers provide information regarding response to therapy. Candidate prognostic biomarkers for breast cancers are growth factor receptors, steroid receptors, Ki-67, cyclins, urokinase plasminogen activator, p53, p21, pro- and anti-apoptotic factors, BRCA1 and BRCA2. But currently, the predictive markers are Estrogen and Progesterone receptors responding to endocrine therapy, and HER-2 responding to herceptin. But there are numerous breast cancer cases, where tamoxifen is ineffective even after estrogen receptor positivity. This lead to search of new prognostic and predictive markers and the number of potential markers is constantly increasing due to proteomics and genomics studies. However, most biomarkers individually have poor sensitivity or specificity, or other clinical value. It can be resolved by studying various biomarkers simultaneously, which will help in better prognosis and increasing sensitivity for chemotherapeutic agents. This review is focusing on growth factor receptors, apoptosis markers, signaling cascades, and their correlation with other associated biomarkers in breast cancers. As our knowledge regarding molecular biomarkers for breast cancer increases, prognostic indices will be developed that combine the predictive power of individual molecular biomarkers with specific clinical and pathologic factors. Rigorous comparison of these existing as well as emerging markers with current treatment selection is likely to see an escalation in an era of personalized medicines to ensure the breast cancer patients receive optimal treatment. This will also solve the treatment modalities and complications related to chemotherapeutic regimens." @default.
- W17295600 created "2016-06-24" @default.
- W17295600 creator A5054227451 @default.
- W17295600 creator A5090380865 @default.
- W17295600 date "2009-01-01" @default.
- W17295600 modified "2023-09-29" @default.
- W17295600 title "Growth Factor Receptors and Apoptosis Regulators: Signaling Pathways, Prognosis, Chemosensitivity and Treatment Outcomes of Breast Cancer" @default.
- W17295600 cites W1518116733 @default.
- W17295600 cites W1542422271 @default.
- W17295600 cites W1628370182 @default.
- W17295600 cites W1701602868 @default.
- W17295600 cites W1870193477 @default.
- W17295600 cites W1870720170 @default.
- W17295600 cites W1964457691 @default.
- W17295600 cites W1971931343 @default.
- W17295600 cites W1972708811 @default.
- W17295600 cites W1975618936 @default.
- W17295600 cites W1976226379 @default.
- W17295600 cites W197699128 @default.
- W17295600 cites W1977552076 @default.
- W17295600 cites W1983165385 @default.
- W17295600 cites W1983551749 @default.
- W17295600 cites W1984207100 @default.
- W17295600 cites W1986179085 @default.
- W17295600 cites W1988818641 @default.
- W17295600 cites W1989095274 @default.
- W17295600 cites W1990624032 @default.
- W17295600 cites W1997006452 @default.
- W17295600 cites W1999463736 @default.
- W17295600 cites W2001155346 @default.
- W17295600 cites W2006174096 @default.
- W17295600 cites W2010174111 @default.
- W17295600 cites W2011174531 @default.
- W17295600 cites W2012173926 @default.
- W17295600 cites W2016710415 @default.
- W17295600 cites W2017323433 @default.
- W17295600 cites W2024651005 @default.
- W17295600 cites W2027139228 @default.
- W17295600 cites W2031389814 @default.
- W17295600 cites W2034911143 @default.
- W17295600 cites W2036450457 @default.
- W17295600 cites W2037929312 @default.
- W17295600 cites W2045389096 @default.
- W17295600 cites W2051508079 @default.
- W17295600 cites W2054299932 @default.
- W17295600 cites W2054361195 @default.
- W17295600 cites W2054681435 @default.
- W17295600 cites W2055470380 @default.
- W17295600 cites W2058591356 @default.
- W17295600 cites W2072787342 @default.
- W17295600 cites W2075477970 @default.
- W17295600 cites W2085789195 @default.
- W17295600 cites W2086753528 @default.
- W17295600 cites W2086785691 @default.
- W17295600 cites W2087877138 @default.
- W17295600 cites W2093628776 @default.
- W17295600 cites W2105877961 @default.
- W17295600 cites W2107696861 @default.
- W17295600 cites W2107859602 @default.
- W17295600 cites W2109585569 @default.
- W17295600 cites W2110444464 @default.
- W17295600 cites W2111703821 @default.
- W17295600 cites W2115007832 @default.
- W17295600 cites W2115581335 @default.
- W17295600 cites W2116937653 @default.
- W17295600 cites W2117025246 @default.
- W17295600 cites W2119270486 @default.
- W17295600 cites W2124608032 @default.
- W17295600 cites W2126724373 @default.
- W17295600 cites W2128840922 @default.
- W17295600 cites W2131994307 @default.
- W17295600 cites W2133886319 @default.
- W17295600 cites W2134627266 @default.
- W17295600 cites W2134979684 @default.
- W17295600 cites W2135608675 @default.
- W17295600 cites W2143600397 @default.
- W17295600 cites W2146384083 @default.
- W17295600 cites W2148788638 @default.
- W17295600 cites W2150699733 @default.
- W17295600 cites W2151501496 @default.
- W17295600 cites W2153586848 @default.
- W17295600 cites W2154094988 @default.
- W17295600 cites W2156094924 @default.
- W17295600 cites W2157681182 @default.
- W17295600 cites W2158077354 @default.
- W17295600 cites W2159796173 @default.
- W17295600 cites W2160450758 @default.
- W17295600 cites W2165055217 @default.
- W17295600 cites W2169222051 @default.
- W17295600 cites W2176579253 @default.
- W17295600 cites W2254593122 @default.
- W17295600 cites W2315404161 @default.
- W17295600 cites W2318605753 @default.
- W17295600 cites W2335279885 @default.
- W17295600 cites W323078090 @default.
- W17295600 cites W4212936275 @default.
- W17295600 cites W4249948852 @default.
- W17295600 doi "https://doi.org/10.4137/bcbcr.s2492" @default.